-
Mashup Score: 3
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking plenary session at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. The goal of the RUBY phase III trial program is to evaluate which patients with primary advanced or recurrent
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer - The ASCO Post - 2 month(s) ago
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or recurrent endometrial cancer, compared to chemotherapy alone. These results were presented in a late-breaking session at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. A post
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Dostarlimab-Based Combinations in Advanced Endometrial Cancer https://t.co/dFFR0syDkF #gyncsm #endometrialcancer #oncology #immunotherapy